Literature DB >> 21041693

Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury.

Mohammad A M Ali1, Woo Jung Cho, Bryan Hudson, Zamaneh Kassiri, Henk Granzier, Richard Schulz.   

Abstract

BACKGROUND: Titin is the largest mammalian (≈3000 to 4000 kDa) and myofilament protein that acts as a molecular spring in the cardiac sarcomere and determines systolic and diastolic function. Loss of titin in ischemic hearts has been reported, but the mechanism of titin degradation is not well understood. Matrix metalloproteinase-2 (MMP-2) is localized to the cardiac sarcomere and, on activation in ischemia/reperfusion injury, proteolyzes specific myofilament proteins. Here we determine whether titin is an intracellular substrate for MMP-2 and if its degradation during ischemia/reperfusion contributes to cardiac contractile dysfunction. METHODS AND
RESULTS: Immunohistochemistry and confocal microscopy in rat and human hearts showed discrete colocalization between MMP-2 and titin in the Z-disk region of titin and that MMP-2 is localized mainly to titin near the Z disk of the cardiac sarcomere. Both purified titin and titin in skinned cardiomyocytes were proteolyzed when incubated with MMP-2 in a concentration-dependent manner, and this was prevented by MMP inhibitors. Isolated rat hearts subjected to ischemia/reperfusion injury showed cleavage of titin in ventricular extracts by gel electrophoresis, which was confirmed by reduced titin immunostaining in tissue sections. Inhibition of MMP activity with ONO-4817 prevented ischemia/reperfusion-induced titin degradation and improved the recovery of myocardial contractile function. Titin degradation was also reduced in hearts from MMP-2 knockout mice subjected to ischemia/reperfusion in vivo compared with wild-type controls.
CONCLUSION: MMP-2 localizes to titin at the Z-disk region of the cardiac sarcomere and contributes to titin degradation in myocardial ischemia/reperfusion injury.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21041693      PMCID: PMC3057897          DOI: 10.1161/CIRCULATIONAHA.109.930222

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  52 in total

1.  Heart failure alters matrix metalloproteinase gene expression and activity in rat skeletal muscle.

Authors:  Robson Francisco Carvalho; Rafael Dariolli; Luis Antonio Justulin Junior; Mário Mateus Sugizaki; Marina Politi Okoshi; Antonio Carlos Cicogna; Sérgio Luis Felisbino; Maeli Dal Pai-Silva
Journal:  Int J Exp Pathol       Date:  2006-12       Impact factor: 1.925

2.  Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction.

Authors:  Marina R Bergman; John R Teerlink; Rajeev Mahimkar; Luyi Li; Bo-Qing Zhu; Anita Nguyen; Sia Dahi; Joel S Karliner; David H Lovett
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-12-08       Impact factor: 4.733

3.  Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2.

Authors:  Grzegorz Sawicki; Hernando Leon; Jolanta Sawicka; Meltem Sariahmetoglu; Costas J Schulze; Paul G Scott; Danuta Szczesna-Cordary; Richard Schulz
Journal:  Circulation       Date:  2005-07-18       Impact factor: 29.690

Review 4.  Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches.

Authors:  Richard Schulz
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

5.  Inhibition of matrix metalloproteinases prevents peroxynitrite-induced contractile dysfunction in the isolated cardiac myocyte.

Authors:  H León; I Baczkó; G Sawicki; P E Light; R Schulz
Journal:  Br J Pharmacol       Date:  2007-12-10       Impact factor: 8.739

6.  Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury.

Authors:  Miranda M Sung; Christina G Schulz; Wenjie Wang; Grzegorz Sawicki; Norma L Bautista-López; Richard Schulz
Journal:  J Mol Cell Cardiol       Date:  2007-07-31       Impact factor: 5.000

7.  Increased activities of cardiac matrix metalloproteinases matrix metalloproteinase (MMP)-2 and MMP-9 are associated with mortality during the acute phase of experimental Trypanosoma cruzi infection.

Authors:  Fredy Roberto Salazar Gutierrez; Manoj Mathew Lalu; Flávia Sammartino Mariano; Cristiane Maria Milanezi; Jonathan Cena; Raquel Fernanda Gerlach; Jose Eduardo Tanus Santos; Diego Torres-Dueñas; Fernando Queiróz Cunha; Richard Schulz; João Santana Silva
Journal:  J Infect Dis       Date:  2008-05-15       Impact factor: 5.226

8.  Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia-reperfusion injury.

Authors:  William E Stansfield; Nancy C Moss; Monte S Willis; Ruhang Tang; Craig H Selzman
Journal:  Ann Thorac Surg       Date:  2007-07       Impact factor: 4.330

9.  The role of nitric oxide in cardiac depression induced by interleukin-1 beta and tumour necrosis factor-alpha.

Authors:  R Schulz; D L Panas; R Catena; S Moncada; P M Olley; G D Lopaschuk
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

10.  Caveolin-1 inhibits matrix metalloproteinase-2 activity in the heart.

Authors:  A K Chow; J Cena; A F El-Yazbi; B D Crawford; A Holt; W J Cho; E E Daniel; R Schulz
Journal:  J Mol Cell Cardiol       Date:  2007-02-01       Impact factor: 5.000

View more
  54 in total

1.  Expression of soluble and functional full-length human matrix metalloproteinase-2 in Escherichia coli.

Authors:  Andrezza N Gonçalves; Cesar A Meschiari; William G Stetler-Stevenson; M Cristina Nonato; Cleidson P Alves; Enilza M Espreafico; Raquel F Gerlach
Journal:  J Biotechnol       Date:  2011-10-05       Impact factor: 3.307

Review 2.  Extracellular Matrix in Ischemic Heart Disease, Part 4/4: JACC Focus Seminar.

Authors:  Nikolaos G Frangogiannis; Jason C Kovacic
Journal:  J Am Coll Cardiol       Date:  2020-05-05       Impact factor: 24.094

3.  Sustained Release of a Peptide-Based Matrix Metalloproteinase-2 Inhibitor to Attenuate Adverse Cardiac Remodeling and Improve Cardiac Function Following Myocardial Infarction.

Authors:  Zhaobo Fan; Minghuan Fu; Zhaobin Xu; Bo Zhang; Zhihong Li; Haichang Li; Xinyu Zhou; Xuanyou Liu; Yunyan Duan; Pei-Hui Lin; Pu Duann; Xiaoyun Xie; Jianjie Ma; Zhenguo Liu; Jianjun Guan
Journal:  Biomacromolecules       Date:  2017-08-07       Impact factor: 6.988

Review 4.  Myocardial matrix metalloproteinase-2: inside out and upside down.

Authors:  Ashley DeCoux; Merry L Lindsey; Francisco Villarreal; Ricardo A Garcia; Richard Schulz
Journal:  J Mol Cell Cardiol       Date:  2014-09-28       Impact factor: 5.000

5.  Inhibition of MMP prevents doxorubicin-induced cardiotoxicity by attenuating cardiac intracellular and extracellular matrix remodelling.

Authors:  Inna Rabinovich-Nikitin; Matthew Love; Lorrie A Kirshenbaum
Journal:  Cardiovasc Res       Date:  2021-01-01       Impact factor: 10.787

Review 6.  The extracellular matrix in myocardial injury, repair, and remodeling.

Authors:  Nikolaos G Frangogiannis
Journal:  J Clin Invest       Date:  2017-05-01       Impact factor: 14.808

Review 7.  The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases.

Authors:  Griselda A Cabral-Pacheco; Idalia Garza-Veloz; Claudia Castruita-De la Rosa; Jesús M Ramirez-Acuña; Braulio A Perez-Romero; Jesús F Guerrero-Rodriguez; Nadia Martinez-Avila; Margarita L Martinez-Fierro
Journal:  Int J Mol Sci       Date:  2020-12-20       Impact factor: 5.923

8.  Post-mortem timing of skeletal muscle biochemical and mechanical degradation.

Authors:  Lori J Tuttle; Marianna Alperin; Richard L Lieber
Journal:  J Biomech       Date:  2014-02-19       Impact factor: 2.712

Review 9.  Oxidative stress and sarcomeric proteins.

Authors:  Susan F Steinberg
Journal:  Circ Res       Date:  2013-01-18       Impact factor: 17.367

10.  TIMP3 deficiency exacerbates iron overload-mediated cardiomyopathy and liver disease.

Authors:  Pavel Zhabyeyev; Subhash K Das; Ratnadeep Basu; Mengcheng Shen; Vaibhav B Patel; Zamaneh Kassiri; Gavin Y Oudit
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-01-26       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.